Rhythm Pharmaceuticals Inc. (RYTM) gains 0.40% for July 21

Equities Staff  |

Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) shares gained 0.40%, or $0.08 per share, to close Wednesday at $19.86. After opening the day at $19.90, shares of Rhythm fluctuated between $19.98 and $19.43. 181,549 shares traded hands a decrease from their 30 day average of 394,086. Wednesday's activity brought Rhythm’s market cap to $997,106,214.

Rhythm is headquartered in Boston, Massachusetts..

About Rhythm Pharmaceuticals Inc.

Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for patients living with rare genetic diseases of obesity. Early-onset severe obesity may result from genetic variants within the melanocortin-4 receptor (MC4R) pathway, a key hypothalamic pathway that regulates hunger, caloric intake, and energy expenditure, consequently affecting body weight. Rhythm is developing setmelanotide for the treatment of rare genetic diseases of obesity that arise due to an impaired pathway, as setmelanotide has shown the potential to restore impaired pathway function.

Visit Rhythm Pharmaceuticals Inc.’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Rhythm Pharmaceuticals Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: Rhythm Pharmaceuticals Inc.’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content